Sutro Biopharma, Inc. has appointed Craig Berman, M.D., Vice President of Clinical Development and has promoted Regina Cheng to Vice President of Finance and Controller.

Dr. Craig Berman has more than 17 years of experience in drug development, including immuno-oncology, and most recently was Vice President of Clinical Development at QED Therapeutics. Previously, he was Senior Director of Clinical Development at Halozyme, Executive Director of Clinical Development at Exelixis and Senior Director of Clinical Development at Medivation (acquired by Pfizer).

“Dr. Berman is an accomplished biotech clinical development leader,” said Sutro’s Chief Medical Officer, Arturo Molina, M.D. “His deep experience building high-performing teams and strategic leadership of multiple cancer therapeutic programs through all stages of clinical development will help us advance our innovative pipeline towards registration.”

Ms. Regina Cheng has more than 20 years of financial accounting experience and has managed Sutro’s finance and accounting team since 2015. Prior to joining Sutro, Ms. Cheng held various corporate and divisional controllership management positions at several private and publicly-held technology companies, including CompareNetworks, Inc., TeraRecon (acquired by SymphonyAI Group), Keynote Systems (acquired by Thoma Bravo, LLC), Sungard Data Systems (acquired by FIS) and Sterling Software (acquired by Computer Associates). 

“Regina has built highly successful, results-driven finance and accounting teams in the past and while at Sutro,” said Ed Albini, Sutro’s Chief Financial Officer. “While we continue to advance and grow as a company, Regina delivers the experience, energy and commitment needed to help drive and support our organizational success.”